Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.40 |
| ▸ | RBP4 | P02753 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729556 | 1.00 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1HSD11B1HCRTR1HCRTR2 | |
| SCHEMBL23116387 | 0.84 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1HSD11B1HCRTR1HCRTR2 | |
| SCHEMBL29839290 | 0.84 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1HSD11B1HCRTR1HCRTR2 | |
| SCHEMBL22729499 | 0.83 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1 | |
| SCHEMBL22729779 | 0.83 | ROCK2 (0.43) | HSP90AA1HSP90AB1HCRTR1HCRTR2 | |
| SCHEMBL22729681 | 0.82 | RIPK1 (0.42) | HSP90AA1HSP90AB1HCRTR1HCRTR2 | |
| SCHEMBL29839310 | 0.82 | RIPK1 (0.42) | HSP90AA1HSP90AB1HCRTR1HCRTR2 | |
| SCHEMBL23116410 | 0.81 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1HSD11B1HCRTR1HCRTR2 | |
| SCHEMBL22729509 | 0.81 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1HSD11B1 | |
| SCHEMBL22729502 | 0.77 | RIPK1 (0.47) | HSP90AA1HSP90AB1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | HSP90AA1 3030/4885HSP90AB1 2624/4885HSD11B1 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.